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Background: The current standard for pain control following liver surgery is intravenous, patient-controlled analgesia
(IV PCA) or epidural analgesia. We have developed a modification of a regional technique called medial open
transversus abdominis plane (MOTAP) catheter analgesia. The MOTAP technique involves surgically placed catheters
through the open surgical site into a plane between the internal oblique muscle and the transverse abdominis muscle
superiorly. The objective of this trial is to assess the efficacy of this technique.
Methods/design: This protocol describes a multicentre, prospective, blinded, randomized controlled trial. One
hundred and twenty patients scheduled for open liver resection through a subcostal incision will be enrolled. All
patients will have two MOTAP catheters placed at the conclusion of surgery. Patients will be randomized to one of two
parallel groups: experimental (local anaesthetic through MOTAP catheters) or placebo (normal saline through MOTAP
catheters). Both groups will also receive IV PCA. The primary endpoint is mean cumulative postoperative opioid
consumption over the first 2 postoperative days (48 hours). Secondary outcomes include pain intensity, patient
functional outcomes, and the incidence of complications.
Discussion: This trial has been approved by the ethics boards at participating centres and is currently enrolling
patients. Data collection will be completed by the end of 2014 with analysis mid-2015 and publication by the end of
2015.
Trial registration: The study is registered with http://clinicaltrials.gov (NCT01960049; 23 September 2013)
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Background and rationale
Liver resection is the optimal treatment for patients
with primary or metastatic liver malignancies, benign
liver tumours, and some biliary diseases [1-5]. In
Canada, over 2,000 patients annually undergo liver re-
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article, unless otherwise stated.decades, improvements in surgical technique, better
haemostatic control, and wider indications for liver re-
section, especially for those with metastatic disease, has
resulted in a significant increase in the prevalence of
liver resection surgery. There has been an increase of
approximately 12% in the number of liver resections
performed each year with a cumulative increase over 5
years of more than 60% [7].
Due to the location of the liver and the propensity for
bleeding during resection, surgery is typically performed
through a large right subcostal incision. The subcostal
incision, however, is associated with significant postoperativetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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plications, delayed mobilization and physiotherapy, and
prolonged hospital stay [8]. Inadequate postoperative
pain management is associated with the development of
chronic postsurgical pain which is costly to both the pa-
tient and society [9-12]. Intense postoperative pain is a
risk factor for the development of chronic postsurgical
pain (CPSP) [9-12]. Prolonged pain after surgery is the
result of changes in the peripheral and central nervous
system causing amplification, increased sensitivity, and
prolongation of pain [13]. It is estimated that as many
as 30% of Canadians who undergo an operation will de-
velop CPSP and the severity of acute postoperative pain
is a predictor of its development [14]. Chronic pain is
costly to the patient and society in terms of direct health
care expenditures, and indirect costs associated with
lost productivity, as well as suffering and disability [12].
Aggressive and effective early postoperative pain relief
may prevent the development of chronic pain [11].
Conventional techniques of postoperative analgesia
include epidural catheters, intravenous opioid patient-
controlled analgesia, and peripheral nerve blocks [15-17].
Peripheral nerve blocks - specifically transversus abdom-
inis plane (TAP) blocks - have been described [18-20]. A
modification of the TAP technique which involves surgeon
placement of the TAP catheters directly into the open sur-
gical wound (medial open transversus abdominis plane;
MOTAP) has been investigated both at Sunnybrook
Health Sciences Centre and at the University Health
Network – Toronto General Division [21].Epidural analgesia
Epidural analgesia remains the gold standard for pain
control following an abdominal surgical procedure [22].
However, complications from epidural analgesia include
hypotension, bradycardia dural puncture, spinal infec-
tion, and rarely, but devastatingly, neurological damage
[23-26]. Furthermore, removal of epidural catheters may
provide logistic challenges if patients develop coagulopa-
thy on the basis of liver dysfunction [27-30]. Given the
above risks, many institutions do not routinely insert
epidurals for patients undergoing major liver resection.Intravenous opioid patient-controlled analgesia
Despite the variety of pain-relieving modalities available,
postoperative pain following liver surgery is significant
and remains a challenge to manage. Opioid analgesia,
while effective at rest, fails to provide adequate pain re-
lief associated with movement such as breathing, cough-
ing, ambulation, and gastrointestinal motility [11,31].
Moreover, opioids are associated with adverse effects
such as nausea, vomiting, constipation, sedation, and re-
spiratory depression [20].Transversus abdominis plane
Movement-evoked incisional pain accounts for the ma-
jority of pain experienced, and the nerves responsible
arise from thoracic levels T6 to T10 [32]. These nerves
lie in a plane between the internal oblique and transver-
sus abdominis muscles, known as the TAP [18,33,34].
The TAP block involves injecting local anaesthetics into
this fascial plane, thereby blocking transmission of the
sensory neurons responsible for abdominal surgical pain.
Afferent sensory information from these nerves can be
blocked by infiltrating local anaesthetic via a surgically
placed catheter that runs in the lateral TAP (blocking T8
to T10) and extends into a second adjacent anatomical
compartment, the posterior aspect of the rectus sheath
(blocking T6 to T8). A variation of the TAP block, the
oblique subcostal block, provides sensory blockade for
surgical incisions between T6 and T10 dermatomes, in-
cluding the subcostal or chevron incision used in liver
surgery [18]. A retrospective study of 36 patients demon-
strated that ultrasound-guided TAP blocks significantly
decreased 24-hour cumulative morphine consumption
[19]. A recent randomized controlled trial demonstrated
that TAP blocks and epidural analgesia are equally effica-
cious in controlling postoperative pain [20]. However, due
to the close proximity to the peritoneum and the highly
vascularized liver, single-shot subcostal TAP blocks are
quite challenging to perform, even under ultrasound guid-
ance, as evidenced by two cases of liver puncture in a
sample of 36 patients [19]. In small studies, TAP blocks
decreased postoperative opioid consumption, nausea,
and vomiting, while providing pain control similar to
epidural analgesia [35]. TAP blocks are typically infil-
trated using ultrasound guidance at the conclusion of
the operation. Preliminary uncontrolled studies and
case reports have demonstrated the potential efficacy,
safety, and patient satisfaction of TAP catheters [20,36].
MOTAP technique – modification of the transversus
abdominis plane technique
We have recently developed a modification of the TAP
technique for regional analgesia following subcostal inci-
sions termed MOTAP catheter placement. This technique
involves surgical placement of the catheter under direct
vision. During subcostal incision these muscular planes
are clearly visible, allowing more confident insertion of a
catheter directly into the correct plane [37]. In a pilot
study, 22 fit adults undergoing donor hepatectomies re-
ceived TAP catheters at the end of surgery. The patients
received the first dose of bupivacaine (0.2 cm3/kg 0.125%)
at the end of surgery and this regimen was repeated every
12 hours until postoperative day 3. We compared postop-
erative pain scores and opioid use to historical controls
and found a significant (P < 0.05) difference in cumulative
postoperative opioid (hydromorphone) consumption at 48
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vs 39.1 ± 25.1 mg for patient-controlled analgesia (PCA)).
Primary objective
To assess the impact of MOTAP catheters plus intraven-
ous, patient-controlled analgesia (IV PCA) compared to
the standard of care (that is, IV PCA alone) on opioid
consumption in patients undergoing hepatic resection
requiring a subcostal incision.
Secondary objectives
To assess the effect of MOTAP catheters on:
1. Postoperative pain intensity.
2. Opioid-related adverse effects, including nausea,
vomiting, pruritus, sedation, and postoperative ileus.
3. Time to ambulation, duration of hospital stay and
reduced postoperative pain disability.
4. Post-surgical complications (for example, pneumonia).
5. Incidence and intensity of chronic postsurgical pain.
Methods/design
Study design
This is a multicentre, prospective, blinded, randomized
controlled trial comparing MOTAP catheters plus IV
PCA to standard care (IV PCA alone) in patients undergo-
ing subcostal incision for liver resection. Full inclusion
and exclusion criteria for the trial are summarized in
Table 1. The trial has been approved by the Toronto Aca-
demic Health Sciences Network Research Ethics Boards
from Sunnybrook Health Sciences Centre (178–2013) and
from the University Health Network (12-0493-A).Table 1 MOTAP study inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• >18 years of age • Patients unable to comprehend
instructions, consent, or co-operate
with pain assessment• Undergoing liver resection
using a subcostal incision (upper
midline extension is allowed)
• Incision extends to allow
visualization of internal
oblique and transversus
abdominis muscles
• Allergy to any study medications
• Patient not able to be extubated
postoperatively for any clinical
reason
• Laparoscopic surgery
• Co-existing epidural or intrathecal
analgesia
• Chronic pain disorders or on
long-term opioids (greater than
1 month prior to operation)
• History of substance or alcohol
abuse
• Transplant donor liver resections
Prior right subcostal incision
MOTAP, medial open transversus abdominis plane.Recruitment
Patients meeting the eligibility criteria will be recruited
at the preoperative surgical consent visit or the anaes-
thesia pre-assessment clinic. Information pamphlets
will be provided and written informed consent will be
obtained. At the time of enrolment, patients will complete
baseline questionnaires: the ‘Preoperative Current Pain
and Pain History Questionnaire’, Numeric Rating Scale
(NRS) [30] for Pain Intensity and Pain Unpleasantness,
the Pain Catastrophizing Scale (PCS) [31], the McGill Pain
Questionnaire - Short Form-2 (SF-MPQ-2) [32,33], and
the Hospital Anxiety and Depression Scale (HADS) [34].
Randomization
Patients will be randomized to one of two parallel groups:
experimental (local anaesthetic through MOTAP catheter)
or placebo (normal saline through MOTAP catheter). Each
research pharmacy will have a concealed randomization list
and the appropriate syringes will be dispensed by the phar-
macy. The code will be retained centrally and only revealed
to the investigators once recruitment and data collection is
completed. Randomization will be stratified by centre. A
brief schema and study outline of this trial is summarized
in Figure 1.
Interventions
Preoperative care (both groups)
All patients will undergo routine preoperative testing at
the preadmission clinic to confirm fitness for surgery
(medical history, electrocardiogram, blood work, and so
forth). No additional tests are required beyond standard-
of-care for patients undergoing liver resection.
Intraoperative care (both groups)
Patients will undergo routine anaesthesia and liver sur-
gery with no additional requirements for this study. No
preoperative oral analgesics are permitted, including
non-steroidal anti-inflammatory drugs, gabapentin, and
acetaminophen. Epidural catheters, intravenous lido-
caine, and ketamine are not permitted. Surgery will be
performed through a right subcostal incision. An upper
midline extension or limited left subcostal extension is
permitted. All aspects of the liver resection will be left
to the surgeon’s discretion. Local anaesthetic may not be
infiltrated into the surgical wound.
Insertion of MOTAP catheters (both groups)
Following liver resection, the operating surgeon will insert
two catheters. The following muscles will be identified:
rectus abdominis, transversus abdominis, internal oblique,
and external oblique. The surgeon will dissect between
the internal oblique and transversus abdominis fascia su-
periorly to open the TAP. A plane will also be developed
between the rectus muscle and the posterior sheath. The
Figure 1 MOTAP study schema and study outline. IV, intravenous; MOTAP, medial open transversus abdominis plane; PCA, patient-controlled
analgesia.
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lary line, between the transversus and internal abdominal
muscles. The second catheter will be sited at the lateral
border of the right rectus abdominis muscle, between the
posterior rectus sheath and the rectus abdominis muscle.
Approximately 10 cm of catheter will be left in each plane,
and tunnelled to skin sites distal to insertion. The cathe-
ters will be secured under occlusive sterile dressing, and
covered with tape. The skin will be closed using either sta-
ples or suture at the surgeon’s discretion. The catheter will
be fastened to the skin using steri-strips and an occlusive
sterile dressing. For the TAP catheter we will use the
001159-20D InfiltraLong 600 T (manufacturer Pajunk,
Germany) and we will use a standard three-orifice cath-
eter for the rectus space.
The study lead at each site will be responsible for en-
suring that all participating surgeons adhere to this tech-
nique of MOTAP insertion. Prior to enrolling a patient,
each participating surgeon must perform at least one
MOTAP insertion with the site’s lead present to become
credentialed in the technique. We will audit the inser-
tion technique of each surgeon at least every five cases
to ensure consistency.
Experimental group - local anaesthetic infusion through
MOTAP
At the conclusion of surgery, both catheters will be
bolused with 20 ml ropivacaine 0.2% followed by a con-
tinuous infusion through each catheter of ropivacaine
0.2% 5 ml per hour.
Control group – normal saline infusion through MOTAP
At the conclusion of surgery, patients in the control
group will have 0.9% normal saline 20 ml bolused then a
5 ml/hour infusion into each catheter.Postoperative care (both groups)
Patients in both groups will be prescribed celecoxib 200
mg orally twice daily (if baseline serum creatinine is less
than 90 μmol/l), and IV PCA hydromorphone 0.2 mg
bolus with a lockout time of 5 minutes and no back-
ground infusion. If patients have inadequate analgesia
with this regimen the bolus dose will be increased to 0.2
to 0.4 mg bolus and the TAP catheter infusions will be
increased to 7.5 ml/hour in each catheter. If pain is still
inadequately controlled, patients will be started on a
continuous intravenous infusion of hydromorphone 0.2
mg/hour in addition to the bolus PCA dosing. If pain is
still inadequately controlled, the study coordinator will
be contacted and the patient assessed by the study site
lead.
Patients may receive additional opioid boluses to con-
trol acute intractable pain while the IV PCA dose is be-
ing adjusted, at the discretion of the acute pain service
clinician or the post-anaesthesia care unit nurse caring
for the patient. These doses will be recorded and in-
cluded in the measurement of total opioid consumption.
Serum creatinine will be monitored daily in the post-
operative period and, if it increases above 90 μmol/l, the
celecoxib will be discontinued; however, patients will re-
main in the trial.
The MOTAP catheters will be removed on the morn-
ing of postoperative day 3 in all patients.Blinding
This will be a blinded, placebo-controlled study. All pa-
tients, clinicians, and data collectors will be unaware of
the group allocation. A pharmacist not involved in pa-
tient care will dispense the study medications according
to the computer-generated randomization list.
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Primary outcome
The primary endpoint is mean cumulative postoperative
opioid consumption over the first 2 postoperative days
(48 hours). Both IV PCA opioids and oral opioids will be
recorded from the patient’s medical records daily, con-
verted to morphine equivalents, and compared between
the two groups.
The following information will be collected at regular
intervals as a measure of the primary endpoints: cumula-
tive IV PCA opioid consumption every 12 hours for 72
hours as well as total opioid consumption for the entire
hospital stay.
Secondary outcomes
We will collect the following secondary patient-reported
outcome scores:
1. NRS [30] scores for pain at rest and with coughing
(0 = no pain, 10 =worst possible pain) three times daily
(TID) for 48 hours and then daily until discharge.
2. Preoperative Current Pain and Pain History
Questionnaire, NRS for Pain Intensity and Pain
Unpleasantness, PCS [31], SF-MPQ-2 [32,33], Pain
Disability Index (PDI) [36,37], and HADS [34] at
baseline.
3. NRS patient satisfaction scores regarding pain control
(0 = totally satisfied, 10 = totally dissatisfied) TID for
the first 48 hours and then daily until discharge.
4. NRS for Pain Intensity and Pain Unpleasantness,
PCS [31], SF-MPQ-2 [32,33], and HADS [34] on the
day of discharge.
5. Long-term pain Follow-Up Pain Questionnaire, PDI
[36,37], PCS [31], SF-MPQ-2 [32,33], HADS [34],
and The Follow-Up Questionnaire 6 months following
surgery (via a routine follow-up telephone call).
6. In-hospital opioid-related side effects - presence of
nausea, vomiting, pruritus, and dizziness (assessed
TID for the first 48 hours, then daily until discharge).
7. Sedation scores, measured TID for the first 48
hours, then daily until discharge using a standard
sedation scale (0 = alert, 1 = mild (occasionally
drowsy, easy to arouse), 2 = moderate (frequently
drowsy, easy to arouse), 3 = severe (somnolent,
difficult to arouse), S = normal sleep, easy to arouse).
8. Duration of hospital stay.
9. Time to first bowel movement.
10. Time to ambulation.
11. Incidence of in-hospital complications, graded using
the Clavien classification [38].
Criteria for removal from study
If, at any time, the patient is found to be ineligible for
the protocol as designated in the section on eligibilitythe patient will be removed from the study. Patients who
are not extubated within 4 hours from the end of the
operation or who are reintubated within 48 hours from
the end of the operation (including a return to the oper-
ating room) will also be excluded from the primary ana-
lysis, although we will continue to follow them while in
hospital. Patients who wish to withdraw from the study
at any point in time will be able to do so.
Data analysis
All statistical analyses will be performed using SAS soft-
ware version 9.2 (SAS Inc., Cary, NC, USA). All tests
will be two-sided and significance will be considered at
P < 0.05.
Primary analysis
Mean cumulative postoperative opioid consumption
during the first postoperative 48 hours will be reported
for the two groups as mean ± standard deviation. The
two groups will be compared using a two sided t-test.
Secondary outcomes
Outcomes will be reported for the two groups as mean ±
standard deviation for normally distributed variables and
the median and interquartile range for nonparametric var-
iables. The two groups will be compared using chi-square
tests, two sample Student’s t-test or the Wilcoxon rank-
sum test as appropriate. Time-to-event outcomes will be
defined from the completion of surgery until the time of
event. Patients who do not have the event at last follow-
up will be censored. The number of censored events is ex-
pected to be low as both events (ambulation and bowel
movements) are requirements prior to the patient’s dis-
charge from hospital. Time to event outcomes will be ana-
lyzed using the Kaplan-Meier method and survival curves
will be compared between the two groups using the log-
rank test.Sample size calculation
Our pilot data consisted of 111 patients that had under-
gone liver resection surgery between April 2004 and Janu-
ary 2009 prior to the use of MOTAP catheters when
postoperative pain relief was provided by IV PCA hydro-
morphone alone. Cumulative hydromorphone consump-
tion over the first 48 hours after surgery was 39.09 ± 25.07
mg. Based on our experience with the use of MOTAP
catheters following adult liver donation surgery, we have
found a reduction of 47% in mean cumulative opioid con-
sumption over the first 2 postoperative days (48 hours).
Patients receiving MOTAP catheters consumed a mean ±
SD of 20.81 ± 15.8 mg of hydromorphone. The difference
of approximately 18 mg over 48 hours is clinically signifi-
cant and represents a reduction of almost 50%.
To be conservative, we will estimate a relative reduc-
tion in mean cumulative opioid consumption of 40%.
Assuming a baseline opioid consumption of 39.09 mg
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patients per group will achieve 90% power at a signifi-
cance level (alpha) of 0.05. We will round up to 120 pa-
tients in total (60 patients in each group).
Discussion
Data from this study will help us optimize postoperative
pain management in patients undergoing liver resection.
It will assist us in developing a standardized protocol for
pain management for these operations. Based on the re-
sults of this work, we hope to further test the efficacy of
these catheters in other surgical cohorts in which upper
abdominal incisions are used and where central neurax-
ial blocks are either contraindicated or refused by the
patient. Better control of pain will help improve patient’s
pain experience, mobilization and physiotherapy follow-
ing surgery, reduce pain disability and possibly decrease
the incidence and intensity of CPSP.
Trial status
This trial has been approved by the ethics boards at par-
ticipating centres and is currently enrolling patients.
Data collection will be completed by the end of 2014
with analysis mid-2015 and publication by the end of
2015.
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